Activation of PP2A via FTY-720 (inhibitor of the PP2A inhibitor protein SET) treatment and the overexpression of B56α was sufficient to impair mutant SF3B1 tumor progression (113, 114, 115). This evidence concerns the gene PTPA and neoplasm.